Corsair Gaming Inc vs Cassava Sciences Inc — how do they compare? Corsair Gaming Inc trades at $12.96 (market cap $1.39B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Corsair Gaming Inc is far larger — about 29.1× Cassava Sciences Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| CRSR | FLNA | |
|---|---|---|
Market Cap | $1.39B | $47.75M |
Sector | Technology | Health |
52-Week High | $14.35 | $4.64 |
52-Week Low | $4.58 | $0.87 |
Enterprise Value | $1.38B | -$34.93M |
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $12.96, down 5.47% today, but maintains a bullish technical signal with strong moving average support. Recent Q2 2026 earnings beat expectations with EPS of $0.23 versus $0.07 expected, and the company raised full-year guidance. Revenue for 2025 was $1.47 billion, though net income was negative $16.16 million, reflecting a net margin of -1.1%. The stock's valuation shows a P/E of 41.39 and P/S of 0.95, with analyst consensus leaning toward Hold but with a $12.40 price target slightly below current levels.
The outlook for CRSR is mixed; strong earnings beats and raised guidance signal operational improvement, but profitability remains a challenge with inconsistent net income. Key risks include competitive pressures in gaming hardware and reliance on consumer spending cycles. Upside potential hinges on sustained margin expansion and successful integration of recent acquisitions like Trak Racer.
FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.
The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.
Trailing returns across standard periods
Latest headlines on both assets
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →